Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminosalicylate sodium is a bacteriostatic antitubercular agent used in the treatment of tuberculosis, particularly in multi-drug resistant (MDR-TB) cases or as a component of retreatment regimens. As the sodium salt of para-aminosalicylic acid (PAS), it functions as a prodrug that interferes with folic acid synthesis in *Mycobacterium tuberculosis*. Specifically, it acts as a competitive inhibitor of dihydropteroate synthase, mimicking para-aminobenzoic acid (PABA). Due to its potential for gastrointestinal irritation, it is frequently formulated as enteric-coated tablets. While an older agent in the antitubercular pharmacopeia, it remains a critical second-line therapy when primary agents like streptomycin or rifampicin are unsuitable or resisted.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminosalicylate sodium.